CpG 7909: Coley began a U.S. Phase I trial of CpG 7909 given in combination with Rituxan rituximab from Idec Pharmaceuticals Corp. (IDPH, San Diego, Calif.) and

Coley Pharmaceutical Group Inc., Wellesley, Mass. Product: CpG 7909 Business: Cancer Therapeutic category: Adjuvant, Immune stimulation Target: Immune cells Description: CpG-containing oligonucleotid...